Mexico’s National Antitrust Commission (CNA) authorized the change in control of pharmaceutical distributor Grupo Comercial e Industrial Marzam earlier this year, according to information released by the company, as a separate legal dispute over the share sale continues in court.
The CNA approved the transaction unanimously on March 23, 2026, under case CNT-119-2025, determining that the concentration did not affect competition or free market participation. On April 8, the commission’s Technical Secretariat confirmed that the transaction had closed under the terms previously notified and authorized.
Marzam publicized the information in a statement published September 14 in Reforma, saying the regulatory decision provides certainty about its corporate structure and its ongoing relationships with customers, suppliers, financial institutions and other pharmaceutical industry participants.
Federal Court Suspends Local Nullity Declaration
The company is also facing a separate legal challenge involving the share purchase agreement.
According to Marzam, Nueva Tierra Finance B.V. sought to have the share sale declared null before a civil court in Mexico City. On September 2, however, the First District Judge for Civil Matters in Mexico City granted a suspension with restitutory effects.
The order requires the share purchase agreement to continue producing its legal effects while the related constitutional proceeding, or amparo, moves forward. The authority involved in the local proceeding must also refrain from carrying out acts related to the nullity declaration during the case.
Marzam said the federal court also recognized that the transaction had been closed before the competent authority.Mexico’s National Antitrust Commission (CNA) authorized the change in control of pharmaceutical distributor Grupo Comercial e Industrial Marzam earlier this year, according to information released by the company, as a separate legal dispute over the share sale continues in court.
The CNA approved the transaction unanimously on March 23, 2026, under case CNT-119-2025, determining that the concentration did not affect competition or free market participation. On April 8, the commission’s Technical Secretariat confirmed that the transaction had closed under the terms previously notified and authorized.
Marzam publicized the information in a statement published September 14 in Reforma, saying the regulatory decision provides certainty about its corporate structure and its ongoing relationships with customers, suppliers, financial institutions and other pharmaceutical industry participants.
Federal Court Suspends Local Nullity Declaration
The company is also facing a separate legal challenge involving the share purchase agreement.
According to Marzam, Nueva Tierra Finance B.V. sought to have the share sale declared null before a civil court in Mexico City. On September 2, however, the First District Judge for Civil Matters in Mexico City granted a suspension with restitutory effects.
The order requires the share purchase agreement to continue producing its legal effects while the related constitutional proceeding, or amparo, moves forward. The authority involved in the local proceeding must also refrain from carrying out acts related to the nullity declaration during the case.
Marzam said the federal court also recognized that the transaction had been closed before the competent authority.
Marzam Says Operations Continue Without Disruption
Despite the legal dispute, Marzam says its commercial and administrative operations remain fully active in Mexico.
The distributor supplies several parts of the private pharmaceutical market through its branches and distribution routes. Its customers include pharmaceutical laboratories, national and regional pharmacy chains, independent pharmacies and purchasing groups, as well as grocery stores and hospitals.
The company said its commercial, financial and contractual relationships remain in force and that its management bodies continue to operate normally.
Marzam also said its new representatives have increased their presence and engagement with participants across the pharmaceutical industry, including major laboratories.
Company Outlines Growth Plans
With the antitrust authorization and federal court suspension as part of its current legal position, Marzam says it is focused on maintaining its operations and strengthening its presence in Mexico’s private pharmaceutical distribution market.
The company said its immediate objective is to continue growing while maintaining its service and compliance commitments.
Marzam’s public statement also seeks to reassure the broader pharmaceutical supply chain that, according to the company, the ongoing legal dispute has not interrupted its commercial activity or the effects of the shareholding transaction.
Marzam Says Operations Continue Without Disruption
Despite the legal dispute, Marzam says its commercial and administrative operations remain fully active in Mexico.
The distributor supplies several parts of the private pharmaceutical market through its branches and distribution routes. Its customers include pharmaceutical laboratories, national and regional pharmacy chains, independent pharmacies and purchasing groups, as well as grocery stores and hospitals.
The company said its commercial, financial and contractual relationships remain in force and that its management bodies continue to operate normally.
Marzam also said its new representatives have increased their presence and engagement with participants across the pharmaceutical industry, including major laboratories.
Company Outlines Growth Plans
With the antitrust authorization and federal court suspension as part of its current legal position, Marzam says it is focused on maintaining its operations and strengthening its presence in Mexico’s private pharmaceutical distribution market.
The company said its immediate objective is to continue growing while maintaining its service and compliance commitments.
